Chief executive Dr Ken Taylor said that the company is focused on completing the treatment of group 3 in the Phase IIb clinical trial of NTCELL® for Parkinson’s disease and will announce when this occurs.
The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful
Ann: Appendix 4C - quarterly, page-6
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 6044404 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1428165 | 3 |
View Market Depth
| Last trade - 16.12pm 14/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |
Day chart unavailable